Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience

Aim of the studyTo investigate the characteristics of patients with hepatoblastoma and low serum alpha-fetoprotein (AFP) at diagnosis.Patients and methodsInclusion of all 21 patients accrued onto SIOPEL trials, whose serum AFP was <100 ng/ml at diagnosis. Slides of all 15 patients with available histological material were centrally reviewed.ResultsMedian age: 10 months. Disease extension at diagnosis: PRETEXT group: II (3 patients), III (10 patients) and IV (8 patients). Extra-hepatic extension: 8 patients. Multifocal tumour: 8 patients. Histology at review: wholly epithelial subtype: 11/15 patients including nine with a small-cell undifferentiated histology. Outcome: only 9 patients achieved a partial response and 16 died. Median survival: 4.4 months. Two-year overall survival: 24% (confidence interval 10–45%).ConclusionThis study clearly identifies patients with hepatoblastoma and low serum AFP at diagnosis as a high-risk subgroup with extensive disease at diagnosis, poor response to chemotherapy and a poor outcome.